Phosphoramidic Acid

Phosphoramidic Acid

SCHEMBL109493

NP(=O)(O)O.Nc1ncnc2c1ncn2[C@@H]1O[C@H](C(O)N(CCC(=O)O)CCC(=O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QARS1 P47897 1/20 0.56
PRKACA P17612 1/20 0.54
AHCY P23526 3/20 0.54
HIF1A Q16665 1/20 0.54
TMEM97 Q5BJF2 1/20 0.54
SIGMAR1 Q99720 1/20 0.54
HSP90B1 P14625 4/20 0.54
HSP90AA1 P07900 2/20 0.54
ADORA1 P30542 2/20 0.53
ADORA2A P29274 2/20 0.53
ADORA2B P29275 2/20 0.53
ADORA3 P0DMS8 2/20 0.53
TSHR P16473 1/20 0.53
LMNA P02545 1/20 0.53
THRB P10828 1/20 0.53
BLM P54132 1/20 0.53
KMT2A Q03164 1/20 0.53
DNPH1 O43598 1/20 0.53
PRKAB2 O43741 1/20 0.53
TRPM2 O94759 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoramidic Acid SCHEMBL111868 0.95 GNMT (0.56) QARS1PRKACAAHCYHIF1ATMEM97
Phosphoramidic Acid SCHEMBL110548 0.91 AHCY (0.56) QARS1AHCYHIF1ATMEM97SIGMAR1
Phosphoramidic Acid SCHEMBL109783 0.84 POLB (0.50) QARS1PRKACAADORA1DNPH1PRKAB2
Phosphoramidic Acid SCHEMBL112033 0.83 NT5E (0.53)
SCHEMBL6900354 0.80 AHCY (0.60) PRKACAAHCYHIF1ATMEM97SIGMAR1
SCHEMBL6402599 0.80 AHCY (0.62) AHCYHIF1ATMEM97SIGMAR1HSP90B1
SCHEMBL14696726 0.80 PRKACA (0.61) QARS1PRKACAAHCYHIF1ATMEM97
SCHEMBL6900339 0.80 AHCY (0.60) PRKACAAHCYHIF1ATMEM97SIGMAR1
Phosphoramidic Acid SCHEMBL2690062 0.80 POLB (0.49) QARS1PRKACAAHCYHIF1ATMEM97
Phosphoramidic Acid SCHEMBL109796 0.79 NT5E (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108533-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2012-05-03 US disclosed
EP-2424874-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-03-07 EP disclosed
WO-2010125200-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108533-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS PNP, TYMP, MTAP QARS1 1269/4885PRKACA 1534/4885AHCY 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.